Hamadi Almotlak
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Renal cell carcinoma treatment, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)(2020)164 cited
- → Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study(2022)40 cited
- → Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer(2022)40 cited
- → Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability(2023)38 cited
- → Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma(2014)34 cited
- → Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients(2021)33 cited
- → Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC(2019)28 cited
- → Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice(2021)28 cited
- → FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study(2020)17 cited
- → Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study(2015)16 cited